(MedPage Today) — At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) is being adopted outside of…
Source link : https://www.medpagetoday.com/meetingcoverage/ashfuturefocusdlbcl/119127
Author :
Publish date : 2025-12-22 15:55:00
Copyright for syndicated content belongs to the linked Source.
